Sarepta Therapeutics Inc
(LTS:0L35)
$
121.67
0 (0%)
Market Cap: 11.61 Bil
Enterprise Value: 11.80 Bil
PE Ratio: 78.90
PB Ratio: 9.50
GF Score: 82/100 Sarepta Therapeutics Inc at UBS BioPharma Conference Transcript
Nov 09, 2023 / 02:00PM GMT
Release Date Price:
$79.37
(-1.67%)
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst
Well, good morning, and welcome to day 2 of the UBS Biopharma Conference. I'm Colin Bristow, one of the biotech analysts. It's my pleasure to have Sarepta Therapeutics here with us today. On behalf of the company, we have CFO, Ian Estepan, Ian, thank you for spending the time with us.
Ian Michael Estepan
Sarepta Therapeutics, Inc. - Executive VP & CFO
Thank you so much for having us. And obviously, I'm going to be making some forward-looking statements. So obviously, you should refer to our SEC documents for the appropriate warnings around that.
Questions & Answers
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst
So a busy couple of weeks for you guys. Maybe we could start with just walk us through the chain of events from the unblinding of EMBARK to kind of where we are today.
Ian Michael Estepan
Sarepta Therapeutics, Inc. - Executive VP & CFO
Yes. So obviously
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot